Survodutide vs Mazdutide vs Retatrutide: Dual GLP-1/Glucagon and Triple Agonist Biochemistry
Survodutide (BI 456906) and Mazdutide (IBI362) are acylated dual GLP-1R/GCGR agonists that pair satiety signaling with hepatic glucagon-driven lipid oxidation, whereas Retatrutide (LY3437943) adds potent GIPR agonism as a 39-residue triple receptor agonist.
- Survodutide (BI 456906) is an oxyntomodulin-derived dual GLP-1R/GCGR agonist incorporating a C18 fatty diacid for albumin binding.
- Mazdutide (IBI362 / LY3305677) is a mammalian oxyntomodulin analogue engineered for balanced dual GLP-1R and GCGR signaling.
- Retatrutide (LY3437943) expands the scaffold to triple GLP-1R, GIPR, and GCGR agonism with picomolar GIPR dominance.
- Comparing Survodutide vs Tirzepatide isolates GCGR-driven hepatic steatosis clearance versus GIPR-mediated insulinotropic pathways.
| Survodutide (CAS / MW) | 2805997-46-8 | 4231.65 g/mol | Dual GLP-1R / GCGR |
|---|---|
| Mazdutide (CAS / MW) | 2259884-03-0 | 4563.06 g/mol | Dual GLP-1R / GCGR |
| Retatrutide (CAS / MW) | 2381089-83-2 | 4731.33 g/mol | Triple GLP-1R / GIPR / GCGR |
| Lipidation Strategy | C18/C20 fatty-diacid side chains for reversible serum albumin binding |
| Analytical Verification | ≥99.0% RP-HPLC (C18) + High-Resolution ESI-MS (±0.1 Da) |
| Recommended Storage | Lyophilized -20°C desiccated; reconstituted 2°C–8°C |
1. Survodutide Mechanism of Action: Dual GLP-1R / GCGR Co-Agonism
Survodutide (BI 456906, CAS 2805997-46-8, MW 4231.65 g/mol) is a 29-amino acid acylated peptide engineered from the endogenous gut hormone glucagon/oxyntomodulin template. By combining GLP-1 receptor activation with calibrated glucagon receptor (GCGR) agonism, Survodutide stimulates hepatic β-oxidation, lipolysis, and energy expenditure in preclinical hepatocyte and metabolic models while GLP-1R co-signaling buffers glucagon-induced hyperglycemia. Its C18 fatty-diacid acylation enables reversible albumin binding and enzymatic protection against DPP-4 cleavage.
2. Survodutide vs Mazdutide: Comparing Oxyntomodulin Scaffolds
Both Survodutide and Mazdutide (IBI362 / LY3305677, CAS 2259884-03-0, MW 4563.06 g/mol) are dual GLP-1R/GCGR agonists derived from oxyntomodulin, yet they differ in linker architecture, fatty-diacid chain length (C20 diacid on Mazdutide), and relative GLP-1R:GCGR potency ratios in cAMP accumulation assays. Researchers comparing Survodutide vs Mazdutide evaluate downstream hepatic fat mobilization, amino acid catabolism markers, and receptor internalization kinetics across primary hepatocyte and pancreatic β-cell cultures.
3. Dual GCGR Agonists vs Retatrutide & Tirzepatide
When contrasting Survodutide vs Tirzepatide or Mazdutide vs Tirzepatide, the key experimental axis is GCGR versus GIPR co-activation: Tirzepatide activates GLP-1R and GIPR without meaningful GCGR affinity, whereas Survodutide and Mazdutide engage GLP-1R and GCGR without GIPR signaling. Retatrutide (LY3437943, CAS 2381089-83-2, MW 4731.33 g/mol) unifies all three Class B GPCRs in a single 39-residue backbone, making side-by-side in-vitro assays across Semaglutide, Tirzepatide, Survodutide, Mazdutide, and Retatrutide ideal for dissecting individual receptor contributions to cAMP signaling and mitochondrial thermogenesis.
4. Handling Acylated Incretin Peptides in In-Vitro Assays
Because fatty-diacid acylated peptides are amphiphilic and bind strongly to serum albumin, apparent EC50 values shift markedly depending on BSA/HSA concentration in the assay buffer. Always match albumin concentration (typically 0.1% casein or standardized 1% BSA) across comparative plates, reconstitute lyophilized vials gently in sterile neutral buffer or bacteriostatic water without foaming, and normalize dosing by exact nanomolar concentration using the SwissLab Molarity Calculator.
Peer-Reviewed References & Analytical Standards
- Zimmermann T. et al. (2022). BI 456906 (Survodutide): Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism, 66, 101633. [PMID: 36356832 ↗]
- Ji L. et al. (2021). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults. EClinicalMedicine / Nature Communications pharmacology studies. [PMID: 34950864 ↗]
- Coskun T. et al. (2022). LY3437943 (Retatrutide), a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism, 34(9), 1234–1247. [PMID: 35985340 ↗]
Referenced Laboratory Research Reagents
Batch-verified SwissLab catalog entries cited in this monograph
All analytical monographs and chemical data are published strictly for in-vitro laboratory research and scientific reference. Reagents must be handled by qualified personnel wearing appropriate PPE. Not for human or veterinary use.